MétaCan
Menu
← Back to cohort

Outcomes of chemotherapy/trastuzumab treated locally advanced HER2+ breast cancer in British Columbia between 2005 and 2010.

2016· article· en· W2665750361 on OpenAlexaffabout
Wendie-Lou D. Den Brok, Caroline Speers, Scott Tyldesley, Lovedeep Gondara, Alan Nichol, Caroline Lohrisch

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsMedicineTrastuzumabInternal medicineBreast cancerCohortChemotherapyOncologyCancerStage (stratigraphy)Gynecology

Abstract

fetched live from OpenAlex

e12079 Background: Adding trastuzumab (T) to chemotherapy (CT) improves HER2+ breast cancer (BC) outcomes. With the exception of the NOAH study, neoadjuvant (neo) and adjuvant (adj) trials enrolled few patients (pts) with locally advanced (LA) disease. We performed a retrospective analysis in LA HER2+ BC to better understand prognosis in this disease. Methods: Using the BC Outcomes Unit database, we identified all pts referred to the British Columbia Cancer Agency with clinically (c) LA HER2+ BC between 05/2005 and 12/2010, who received standard neo or adj CT/T. LA was defined as T4Nany, T3N1-3, TanyN2-3. Adj cases with c but not pathological (p) LA stage were excluded. Five-year (5 y) relapse free survival (RFS) and BC specific survival (BCSS) were estimated for the overall cohort, by hormone receptor (HR) status, for neo and adj CT/T, and by pathologic complete response (pCR) in neoadj cases. Results: We identified 380 cases. Median follow up was 6.4 y. Adj (258) and neo (122) cases differed in HR- status (35% vs 43%), inflammatory presentation (1% vs 37%), and disease burden (c T4N1-3 2% vs 35%; cT4N0 1% vs 21%; cT3N1-3 3% vs 33%). Among neo cases, pCR rate was 48% (52% in HR-, 43% in HR+). For adj cases, p stage was T4N1-3 in 3%; T3N1-3 in 20%, and T0-2N2-3 in 77%. The table belowshows 5 y RFS and BCSS estimates. Conclusions: HR- BC had 15% lower 5 y RFS than HR+ disease. Neo cases had higher disease burden, explaining thier worse RFS and BCSS. Higher pCR rate in HR- disease, and better RFS and BCSS for pCR vs non-pCR is consistent with neo trials. Allowing for differences in follow up, stage, and HR status, our results for neo CT/T are similar to those in the NOAH study. They confirm the need to improve therapy in LA HER2+ BC, especially HR- and non-pCR cases. Neo pertuzumab and post-neo TDM-1 may in part address this need. 5-year RFS, BCSS. n (%) 5y RFS %, (95% CI) p-value 5y BCSS%, (95% CI) p-value All 380 75 (71, 80) - 81 (76, 84) - HR+ 230 (61) 82 (76, 86) - 88 (83, 92) - HR- 143 (38) 67 (58, 74) - 70 (61, 76) - Adj 258 (68) 80 (74, 84) 0.002 85 (80, 89) 0.004 Neo 122 (32) 66 (57, 74) 71 (62, 79) pCR yes (26 HR+, 32 HR-, 1 unk) 59 (48) 81 (68, 89) 0.002 85 (72, 92) 0.001 pCR no (34 HR+, 29 HR-) 63 (52) 53 (39, 64) 59 (45, 70)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.067
Threshold uncertainty score0.135

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.002
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.024
GPT teacher head0.373
Teacher spread0.349 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicBreast Cancer Treatment Studies→French-language works237,207→